Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 2/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21367124 | 0.96 | ACE2 (0.50) | ACE2PRMT6KDM1ACARM1PRMT8 | |
| SCHEMBL4783223 | 0.93 | ACE2 (0.54) | ACE2PRMT6KDM1ACARM1PRMT8 | |
| SCHEMBL13660816 | 0.92 | PRMT6 (0.43) | ACE2PRMT6KDM1ACARM1PRMT8 | |
| SCHEMBL19071988 | 0.88 | ACE2 (0.56) | ACE2PRMT6KDM1ACARM1PRMT8 | |
| SCHEMBL4395015 | 0.87 | ACE2 (0.61) | ACE2PRMT6KDM1ACARM1PRMT8 | |
| SCHEMBL22416471 | 0.86 | ACE2 (0.40) | ACE2PRMT6KDM1ACARM1PRMT8 | |
| SCHEMBL10099919 | 0.86 | CYP2C19 (0.44) | ACE2KDM1ACYP2C19MEN1GLA | |
| SCHEMBL10282545 | 0.86 | ACE2 (0.48) | ACE2PRMT6CARM1PRMT8CYP2C19 | |
| SCHEMBL14479170 | 0.85 | CYP2C19 (0.46) | ACE2KDM1ACYP2C19MEN1GLA | |
| SCHEMBL25737704 | 0.84 | PRMT6 (0.60) | ACE2PRMT6CARM1PRMT8PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4105207-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2022-12-21 | — | — | EP | disclosed |
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | INSERM - INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (FR) | 2022-12-08 | — | — | US | disclosed |
| WO-2022093817-A1 | MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS, AND METHODS OF MAKING AND USING SAME | YALE UNIVERSITY (US) | 2022-05-05 | — | — | WO | disclosed |
| US-10968198-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | YALE UNIVERSITY (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3267794-B1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | UNIV YALE (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20190276425-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | UNIV YALE (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190209690-A9 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-07-11 | — | — | US | disclosed |
| US-10336721-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | YALE UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20080280889-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-7429574-B2 | 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| EP-1740574-B1 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| US-6346205-B2 | Rigid polyurethane foams | HUNTSMAN INTERNATIONAL LLC | 2002-02-12 | — | — | US | disclosed |
| US-20010006986-A1 | Rigid polyurethane foams | IMPERIAL CHEMICAL INDUSTRIES PLC | 2001-07-05 | — | — | US | disclosed |
| EP-0935625-B1 | RIGID POLYURETHANE FOAMS | HUNTSMAN INT LLC (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6207725-B1 | REACTING ORGANIC POLYISOCYANATE WITH POLYESTERPOLYOL IN PRESENCE OF BLOWING AGNET AND CATALYST SELECTED FROM 2,2'-DIMORPHOLINODIETHYLETHER, 1-METHYLIMIDAZOLE, AND 4-DIMETHYLAMINOPYRIDINE AND SECOND TERTIARY AMINE CATALYST | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 2001-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | ACE2 1797/4885PRMT6 641/4885KDM1A 1993/4885 |
| US-10968198-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | MIF, MMP12, CSF1R | ACE2 2117/4885PRMT6 1317/4885KDM1A 3944/4885 |
| US-20190209690-A9 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | AARS1, SLC43A1, PHAX | ACE2 1118/4885PRMT6 1756/4885KDM1A 3501/4885 |
| US-10336721-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | MIF, MMP12, CSF1R | ACE2 2117/4885PRMT6 1317/4885KDM1A 3944/4885 |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | ACE2 1980/4885PRMT6 2203/4885KDM1A 2676/4885 |
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | HTT, NTRK2, BDNF | ACE2 4448/4885PRMT6 3271/4885KDM1A 1899/4885 |
| US-20190276425-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | MIF, MMP12, CSF1R | ACE2 2117/4885PRMT6 1317/4885KDM1A 3944/4885 |
| US-20080280889-A1 | Inhibitors of Akt Activity | AKT2, PIK3CA, AKT1 | ACE2 2608/4885PRMT6 918/4885KDM1A 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.